GetTopicDetailResponse(id=bcaf1613940, topicName=SEP-363856, introduction=SEP-363856, content=null, image=null, comments=2, allHits=1820, url=https://h5.medsci.cn/topic?id=16139, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=89692, tagList=[TagDto(tagId=89692, tagName=SEP-363856)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1250886, encodeId=56ea125088613, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, objectTitle=NEJM：非多巴胺D2受體抗精神病藥物SEP-363856療效評估, objectType=article, longId=192413, objectId=9be519241378, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9be519241378, replyNumber=0, likeNumber=108, createdTime=2020-04-18, rootId=0, userName=bshuang, userId=cdcd18, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9be519241378, moduleTitle=NEJM：非多巴胺D2受體抗精神病藥物SEP-363856療效評估, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9be519241378)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250885, encodeId=ecbb125088502, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, objectTitle=治療精神分裂癥：SEP-363856已獲FDA突破性療法認定, objectType=article, longId=165923, objectId=db6a165923d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db6a165923d4, replyNumber=0, likeNumber=98, createdTime=2019-05-14, rootId=0, userName=bshuang, userId=cdcd18, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db6a165923d4, moduleTitle=治療精神分裂癥：SEP-363856已獲FDA突破性療法認定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=db6a165923d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
